Prospective Huntington At Risk Observational Study
NCT00052143 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1001
Last updated 2024-09-03
Summary
The purpose of this study is to define the natural history and experiences of people who are at risk for developing Huntington's disease but who do not know their genetic status.
Conditions
- Huntington Disease
Sponsors & Collaborators
-
National Human Genome Research Institute (NHGRI)
collaborator NIH -
National Institute of Neurological Disorders and Stroke (NINDS)
collaborator NIH -
Huntington Study Group
lead NETWORK
Principal Investigators
-
Ira Shoulson, M.D. · University of Rochester
Eligibility
- Min Age
- 26 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 1999-07-09
- Primary Completion
- 2009-12-17
- Completion
- 2009-12-17
Countries
- United States
- Canada
Study Locations
More Related Trials
-
An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)
NCT06254482 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease
NCT01806896 ·Status: COMPLETED ·Phase: PHASE2
-
Riluzole in Huntington's Disease
NCT00277602 ·Status: COMPLETED ·Phase: PHASE3
-
An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease
NCT04514367 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease
NCT00724048 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease
NCT03225846 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD
NCT04556656 ·Status: COMPLETED ·Phase: PHASE3
-
Drug Interaction With Genes in Parkinson's Disease
NCT01564992 ·Status: UNKNOWN
-
A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease
NCT03761849 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)
NCT05358717 ·Status: COMPLETED ·Phase: PHASE2
-
Non-interventional Observational Study With Pramipexole: Impact on Non-motor Symptoms in Parkinson's Disease
NCT00539214 ·Status: COMPLETED
-
Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021
NCT02342548 ·Status: TERMINATED ·Phase: PHASE2
-
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
NCT02507284 ·Status: COMPLETED ·Phase: PHASE2
-
A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease
NCT06826612 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease
NCT00665223 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease
NCT02006472 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease
NCT07246941 ·Status: RECRUITING ·Phase: PHASE1
-
An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies
NCT03842969 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease
NCT03664804 ·Status: COMPLETED ·Phase: PHASE1
-
Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With Pramipexole
NCT02236728 ·Status: COMPLETED
-
Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease
NCT03225833 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Prospective Single-Timepoint Huntington's Disease Biospecimen Collection Study
NCT05773196 ·Status: RECRUITING
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)
NCT03342053 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease
NCT02494778 ·Status: TERMINATED ·Phase: PHASE2
-
In-Home Care for Patients With PSP and Related Disorders
NCT03552484 ·Status: COMPLETED ·Phase: NA